-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 1st, the Inner Mongolia Autonomous Region Pharmaceuticals Centralized Procurement Network issued a notice that Jiangxi Shanxiang Pharmaceutical Cobenzene Sulfini tablets (specs: 0.2g x 60 tablets) were given a supplementary hanging net at a purchase price of 3990.00 yuan/box, which was officially implemented on September 5, 2020.
Sorafenib was developed by Bayer and approved in September 2006 for the treatment of kidney cancer (trade name: Dojime), followed by the treatment of hepatocellular carcinoma, local late stage or metastatic radioactive iodine (RAI) refragtic differentiated thyroid cancer.
Sorapini successfully entered health care in the 2017 health care negotiations, and the 2019 health insurance expiration follow-up negotiations again cut the price of health insurance, data show that Sorrapini's 2019 health care negotiations after the price of 95 yuan / piece (0.2g), a box (spec: 0.2g x 60 pieces) of the price of about 5700 yuan.
the original research in China after 14 years, domestic generic drugs were finally approved.
August 7, 2020, Jiangxi Shanxiang Pharmaceuticals 4 generic drugs were approved, the first generic in China, the current online price is about 70% of the original research;
The Policy Interpretation of the Notice on the Inclusion of Negotiated Drugs in the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalog for 2019 issued by the State Administration of Health Insurance clearly states that generic drugs automatically fall into the medical insurance catalogue after approval during the validity period of the negotiated drugs, and that the generic drug shall be included in the centralized procurement scope, and the medical insurance department will adjust the payment standards of the generic drug according to the price level of the generic drug.
so that Solafeini generics automatically enter health insurance, its pricing will be a reference to the generic drug Medicare payment standard adjustments.
has grown significantly since it was included in Medicare in 2017, with public data showing that domestic public health service sales have exceeded $1 billion in 2018.
with the approval of generic drugs, the price of sorapinie will be further lowered, but also face the huge risk of being collected.
domestic generic drug companies take advantage of the next batch of collection before the arrival of rapid paving, perhaps can also earn a recovery of part of the cost.
original title: Sorafeini first imitation hanging net price of 3990 yuan / box, 70% of the original research price